Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry
Ang Li(Baylor College of Medicine), Rachel Rosovsky(Harvard University), Ali Raza Khaki(Palo Alto Institute), Rebecca L. Zon(Brigham and Women's Hospital), Monica Li(Baylor College of Medicine), Brian I. Rini(Vanderbilt University Medical Center), Petros Grivas(Seattle Cancer Care Alliance), Julie Fu(Stanford University), Michael A. Thompson(The University of Melbourne), Nicole M. Kuderer, Dimpy P. Shah(The University of Texas MD Anderson Cancer Center), Jeremy L. Warner(Brown University), Daniel G. Stover(Harvard University), Shuchi Gulati(Comprehensive Blood & Cancer Center), Corrie Painter, Toni K. Choueiri(Harvard University), Amro Elshoury, Jean M. Connors(Harvard University), Yu Shyr(Vanderbilt University), Solange Peters(University Hospital of Lausanne), Donna R. Rivera(National Cancer Institute), Christopher R. Friese(University of Michigan), Gilberto Lopes(University of Miami), Surbhi Shah(WinnMed), Gary H. Lyman(University of Washington), Aakash Desai(University of Connecticut), Balázs Halmos(Montefiore Medical Center), Andrew Schmidt(Dana-Farber Cancer Institute), Amit Kulkarni(University of Minnesota), Jaymin Patel(Beth Israel Deaconess Medical Center), Nathan A. Pennell(Cleveland Clinic)
Cited by 8
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k